Having determined the potency and selectivity of our MMP9-targeting preclinical antibodies, we next sought to evaluate the therapeutic potential of MMP9 inhibition in ulcerative colitis, an autoimmune disease that is characterized by elevated circulating levels of MMP9 and of MMP9 expression locally, at sites of active disease [11, 12]. This evidence concerns the gene MMP9 and autoimmune disease.